Lung Cancer

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).

Lung Cancer

Lung cancer is a common and very serious form of cancer, with more than 40,000 people diagnosed with the condition each year in the UK. The symptoms of lung cancer do not present in the early stages, but when symptoms do eventually present, they usually include the following:

Lung Cancer Risk Factors

Lung Cancer Research

Pulmonary Resection in Lung Cancer

Exploring Diversity in Lung Cancer: Impact on Incidence, Prognosis, and Treatment Strategies

Pulmonary Transplant (Lung Transplant)

Lung Cancer Symptoms

Lung Cancer Pathogenesis

Lung Cancer and Electrolyte Imbalances

Lung Cancer Questions

Lung Cancer Causes

Lung Cancer in Women: Understanding the Increasing Risk

See more featured articles »

Immunotherapy: The Future of Lung Cancer Treatment?

Lung Cancer: Radiotherapy and Chemotherapy

Secondary Lung Cancer

What Causes Lung Cancer in Non-Smokers?

Lung Cancer Treatments

Types of Lung Cancer Surgery

Everything You Need to Know About Giving Up Cigarettes

Lung Plethysmography Procedure

Lung Cancer Genetics

What are the Survival Rates for Lung Cancer?

How to Prevent Lung Cancer

Lung Cancer Diagnosis

Epidemiology of Lung Cancer

Carcinogens in Cigarette Smoke

Palliative and End-of-Life Care in Lung Cancer

Lung Cancer Screening Procedure

Lymph Nodes in Lung Cancer

Latest Lung Cancer News and Research

Subcutaneous tarlatamab exhibits low toxicity rates in phase 1b trial

Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b DeLLphi-308 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Phase 2 study highlights flexible dosing options for tarlatamab in relapsed SCLC

Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated for small cell lung cancer (SCLC), according to results from the randomized Phase 2 DeLLphi-309 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

MD Anderson trial challenges local consolidative therapy paradigm in NSCLC

Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), including those with oligometastatic disease, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Neoadjuvant atezolizumab addition quadruples pathological responses in resectable lung tumors

Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone, according to final results from the Phase 3 IMpower030 trial.

12 Sep 2026

Low discontinuation rates confirm manageable safety of iza-bren

An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the global Phase 3 IZABRIGHT-Lung01 registrational study.

12 Sep 2026

Tumor DNA clearance reaches 39% in novel immunomodulator and ADC combination

The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first clinical data from the ongoing Phase 1b/2 BNT324-01 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Protein-based MRI agent detects tiny lung cancer metastases

A multi-institutional research team led by Georgia State University Regents' Professor Emerita of Biochemistry and Biophysical Chemistry Jenny J. Yang has developed a new class of protein-based MRI contrast agent that detects invasive lung cancer and metastatic disease at earlier stages than conventional imaging approaches.

9 Sep 2026

Study shows how the microbiome shapes lung cancer immunotherapy outcomes

Despite the revolutionary impact of immune checkpoint inhibitors on cancer therapy, 60% to 80% of patients with NSCLC still show suboptimal responses.

9 Sep 2026

Is stroke risk higher after a cancer diagnosis?

New research indicates that people with invasive cancer face an elevated risk of experiencing a stroke, especially in the first few months after diagnosis and especially if they have certain types of cancer.

9 Sep 2026

New AI model decodes chemical signals guiding embryonic cell development

As an embryo develops from a small cluster of stem cells, those once "blank slate" cells begin to take on more specialized roles like brain, liver, or muscle cells, and organize themselves into three-dimensional structures such as tissues and organs.

8 Sep 2026

Researchers find greater microplastic burden in lung cancer patients

People with lung cancer are more likely to have microplastics in their lungs and to have larger quantities of microplastics in their lungs, according to research that will be presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain.

4 Sep 2026

Daraxonrasib shows durable responses in RAS-mutant lung cancer

Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC) in a Phase 1/2 trial led by The University of Texas MD Anderson Cancer Center.

2 Sep 2026

Post-surgery immunotherapy may not benefit specific lung cancer patients

A new real-world observational study has found that adding adjuvant immunotherapy after surgery does not significantly improve survival outcomes in patients with resectable non-small cell lung cancer (NSCLC) who have already achieved a pathological complete response (pCR) following neoadjuvant chemoimmunotherapy.

2 Sep 2026

Researchers identify a previously unknown mechanism that can drive cancer cachexia

Researchers at Helmholtz Munich, the Heidelberg Faculty of Medicine at Heidelberg University, the German Center for Diabetes Research (DZD) and the Technical University of Munich (TUM), have identified a previously unknown mechanism that can drive cancer cachexia – a wasting process in the body that primarily affects muscle and fat tissue.

1 Sep 2026